Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03149822
Recruitment Status : Active, not recruiting
First Posted : May 11, 2017
Last Update Posted : July 23, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Colorado, Denver

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : December 18, 2020
Estimated Study Completion Date : December 2021